Allergan-Inamed Deal OK’d By Federal Trade Commission; Closure Imminent
This article was originally published in The Gray Sheet
Executive Summary
Allergan's $3.2 bil. acquisition of aesthetics firm Inamed was set to close March 10, following Federal Trade Commission approval of the deal on March 8